Daniel W Cramer
Overview
Explore the profile of Daniel W Cramer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
7376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collin L, Cushing-Haugen K, Terry K, Goode E, Wu A, Harris H, et al.
Cancer Epidemiol Biomarkers Prev
. 2025 Feb;
PMID: 40009771
Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of...
2.
Webber J, Wollborn L, Mishra S, Vitonis A, Cramer D, Phan R, et al.
Gynecol Oncol
. 2024 Aug;
190:124-130.
PMID: 39180961
Objective: To determine whether a multimodal assay combining serum microRNA with protein biomarkers and metadata improves triage assessment of an adnexal mass. Methods: Serum samples from 468 training subjects (191...
3.
4.
Cramer D, Vitonis A, Fichorova R, Yamamoto H, Mudugno F, Finn O
Cancer Epidemiol Biomarkers Prev
. 2024 Jun;
33(9):1211-1219.
PMID: 38864844
Background: Cancers of ductal origin often express glycoprotein mucin 1 (MUC1), also known as CA15.3, with higher levels leading to poor prognosis. Conversely, anti-MUC1 antibodies develop in some patients, leading...
5.
Meagher N, White K, Wilkens L, Bandera E, Berchuck A, Carney M, et al.
Am J Epidemiol
. 2024 May;
193(9):1242-1252.
PMID: 38775277
Limited estimates exist on risk factors for epithelial ovarian cancer (EOC) in Asian, Hispanic, and Native Hawaiian/Pacific Islander women. Participants in this study included 1734 Asian (n = 785 case...
6.
Ramachandran D, Tyrer J, Kommoss S, DeFazio A, Riggan M, Webb P, et al.
NPJ Genom Med
. 2024 Mar;
9(1):19.
PMID: 38443389
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous...
7.
Cramer D
Front Oncol
. 2023 Oct;
13:1240309.
PMID: 37869082
Estrous cycles are recurring changes in therian mammals induced by estrogen, progesterone, and other hormones culminating in endometrial proliferation, ovulation, and implantation if fertilization occurred. In women, the estrous cycle...
8.
A framework for assessing interactions for risk stratification models: the example of ovarian cancer
Phung M, Lee A, McLean K, Anton-Culver H, Bandera E, Carney M, et al.
J Natl Cancer Inst
. 2023 Jul;
115(11):1420-1426.
PMID: 37436712
Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential interactions between these exposures. We have developed a 4-criterion framework for assessing...
9.
May T, Bernardini M, Lheureux S, Aben K, Bandera E, Beckmann M, et al.
Can J Surg
. 2023 Jun;
66(3):E310-E320.
PMID: 37369443
Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium...
10.
Cramer D, Vitonis A, Huang T, Shafrir A, Eliassen A, Barbieri R, et al.
Cancer Epidemiol Biomarkers Prev
. 2023 May;
32(7):976-985.
PMID: 37127868
Background: Lifetime ovulatory years (LOY) is estimated by the difference between ages at menopause and menarche subtracting time for events interrupting ovulation. We tested whether LOY influences sex hormone levels...